本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

BioLine Rx

3.71
-0.0600-1.59%
盤後3.710.00000.00%19:16 EDT
成交量:1.94萬
成交額:7.13萬
市值:1,380.49萬
市盈率:-2.70
高:3.81
開:3.65
低:3.62
收:3.77
52周最高:32.26
52周最低:2.30
股本:372.10萬
流通股本:354.32萬
量比:0.44
換手率:0.55%
股息:- -
股息率:- -
每股收益(TTM):-1.3764
每股收益(LYR):-4.6176
淨資產收益率:-45.94%
總資產收益率:-15.36%
市淨率:0.69
市盈率(LYR):-0.80

資料載入中...

2021/01/11

SEC問詢函

CORRESP [Cover] - Correspondence
2021/01/06

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/11/23

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/11/03

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/07/01

SEC問詢函

CORRESP [Cover] - Correspondence
2020/06/26

招股説明書

F-1 - Registration statement for certain foreign private issuers
2020/06/05

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/06/05

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/06/05

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/06/02

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/05/26

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/05/20

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/12

年度報告

Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/03/12

財報披露

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/05

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/27

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/14

超過5%披露

Statement of acquisition of beneficial ownership by individuals
2020/02/07

超過5%披露

[Amend] Statement of acquisition of beneficial ownership by individuals
2020/01/30

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/01/22

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]